How Does Teva Plan to Generate Cash Flows to Reduce Its Debt?
As of December 31, 2017, Teva Pharmaceutical (TEVA) has debt of $32.5 billion compared to $35.8 billion at the end of 2016. The company has a debt payment of ~$3.5 billion due in fiscal 2018. Teva plans to pay down its debt using its operating cash flows and the cash flows resulting from its divestment of certain noncore and nonprofitable assets as part of its restructuring plan.